It prevents enrollment decisions from being influenced by knowledge of the next treatment assignment. If researchers or participants could anticipate that assignment, they might consciously or unconsciously alter who enters the study. Keeping upcoming assignments inaccessible preserves the intended randomization process, making treatment groups more comparable before interventions begin and improving confidence in later comparisons.
The timing protects the boundary between recruitment and assignment. Concealing the sequence before formal enrollment prevents knowledge of an upcoming allocation from affecting whether a person is entered into the trial. Once enrollment has occurred, the assignment can be released according to the planned process, preserving the study’s randomized structure rather than allowing enrollment choices to shape it.
Allocation concealment addresses knowledge of the upcoming assignment before enrollment and allocation occur. Blinding addresses knowledge of the assigned treatment after allocation, limiting awareness during the study. These safeguards operate at different stages and protect against different sources of influence, so a trial can require both even though concealment concerns the recruitment and assignment process.
Central randomization, sequentially numbered opaque sealed envelopes, and an independent pharmacy service are mechanisms described for protecting the sequence. Each keeps the next assignment inaccessible until the participant is formally entered. Their shared purpose is not to generate the random sequence, but to control when that sequence becomes available during enrollment and treatment assignment.
First, a random treatment sequence is generated. The assignments are then placed under the control of a concealment mechanism, such as central randomization, sequentially numbered opaque sealed envelopes, or an independent pharmacy service. After a participant is formally enrolled, the appropriate assignment is released. This workflow separates sequence creation from access during recruitment.
Readers should determine whether the report identifies a concrete method for keeping upcoming assignments inaccessible until enrollment, rather than simply stating that participants were randomized. Descriptions such as central randomization, sequentially numbered opaque sealed envelopes, or an independent pharmacy service provide evidence that the assignment process was actively protected.
Effective concealment strengthens the comparability of treatment groups at the point of enrollment. That matters because differences observed later can be interpreted with greater confidence as reflecting the interventions rather than decisions about which patients entered the study. In medical research, this supports more credible conclusions from randomized controlled trial comparisons.